Compared with either single therapy, the combination group significantly prolonged tumor-bearing mouse survival, protected most mice from a tumor rechallenge and further augmented increases in local and systemic CD8+ T cells and in plasma IFN-γ. This evidence concerns the gene IFNG and neoplasm.